^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
Colorectal cancer...the panel recommends against the use of mitomycin, alfa-interferon, taxanes, methotrexate, pemetrexed, sunitinib, sorafenib, erlotinib, or gemcitabine, either as single agents or in combination, as therapy in patients exhibiting disease progression after treatment with standard therapies.
